Record FY2024 results with 9% revenue and 24% EBITDA growth, driven by recurring revenues and expansion in medical equipment and radio-pharmaceuticals. Strategic spin-off of R&D segment into Syn2bio and exclusive distribution deals position the group for continued growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.